Reliant AI launches AI-powered analytics for the life sciences with $11.3M in seed funding
Reliant AI, a new generative AI-powered data analytics provider, has launched its first product Reliant Tabular to help the biopharma industry quickly find scientific evidence and accelerate decision-making, backed by $11.3 million in seed funding from Tola Capital and Inovia Capital.
Reliant AI has announced it is emerging from stealth after raising $11.3 million in seed funding in a round co-led by Tola Capital and Inovia Capital, with support from angel investor Mike Volpi. Reliant AI was founded by Karl Moritz Hermann, Marc Bellemare and Richard Schlegel, former team leads at DeepMind, Google Brain, and EY Parthenon to automate repetitive and time-consuming work for enterprises, starting with the biopharma industry, so "highly skilled professionals are focused on wrangling data, rather than solving complex issues."
The company's first product, Reliant Tabular, is an AI-powered workbench that allows analysts in the life sciences to find scientific evidence to back their decision-making. In more practical terms, Tabular is meant to assist analysts in streamlining processes like literature reviews, where researchers often have to manually go over thousands of publications to find the small number that are relevant for their purposes.
Since this is something that out-of-the-box foundational models still struggle with, ensuring accuracy meant that Reliant had to do things such as developing proprietary models optimized for biopharma knowledge and augmenting its product with other techniques to ensure accurate fact-finding, maximize recall, simplify the process of reconciling results with ground truth evidence, and produce shareable outputs that enable easy collaboration.
Early adopters and investors are confident in Reliant AI's potential to streamline and optimize data analysis for the life sciences. Tola Capital Partner Aaron Fleishman highlighted Reliant Tabular's capability to enable "a day's worth of data wrangling to be done in 30 seconds," while Miguel Silva, Strategy Director at OMass Therapeutics, noted that Reliant Tabular has increased his efficiency by parsing relevant data, enabling him to perform deeper analysis and achieve faster turnaround times. Reliant AI plans to leverage the funds to grow its team and expand its technology investments and market presence in North America and Europe.
